<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10K/A
                                   AMENDMENT 1

         |X|      ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                  SECURITIES EXCHANGE ACT OF 1934

                   FOR THE FISCAL YEAR ENDED DECEMBER 31, 2002

                                       OR

         |_|      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                  SECURITIES EXCHANGE ACT OF 1934

                        FOR THE TRANSITION PERIOD FROM TO

                         COMMISSION FILE NUMBER 0-49824

                           INAMCO INTERNATIONAL CORP.
             (Exact name of registrant as specified in its charter)

             DELAWARE                                       72-1359595
 (State or other jurisdiction of                         (I.R.S. Employer
  incorporation or organization)                        Identification No.)

 801 MONTROSE AVE., SOUTH PLAINFIELD, NJ                       07080
 (Address of principal executive offices)                   (Zip Code)

                          (908) 754-4880 (Registrant's
                     telephone number, including area code)


        Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                                     Yes |X|    No |_|

<PAGE>

        Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K (Section 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of the registrant's knowledge, in
the definitive proxy or information statements incorporated by reference in Part
III of this Form 10k or any amendment to this Form 10k |_|

        The approximate aggregate market value of the voting and non-voting
common equity held by non-affiliates of the registrant was approximately
$276,000 as of July 30, 2003, based upon the closing price of the Common
Stock as reported on the Nasdaq Stock Market Pink Sheets on such date. For
purposes of this calculation, shares of Common Stock held by directors and
officers and stockholders whose ownership in the registrant is known by the
registrant to exceed five percent have been included. This number is provided
only for purposes of this report and does not represent an admission by either
the registrant or any such person as to the status of such person.

         As of July 30, 2003 there were 27,600,000 shares of the registrant's
Common Stock outstanding.

<TABLE>
<CAPTION>
                           INAMCO INTERNATIONAL CORP.

                                      INDEX
NO.                                                                                                   PAGE
---                                                                                                   ----

<S>             <C>                                                                                   <C>
Item 1.         Business                                                                                3
Item 2.         Properties                                                                              8
Item 3.         Legal Proceedings                                                                       8
Item 4.         Submissions of Matters to a Vote of Security Holders                                    8

Item 5.         Market for the Registrant's Common Equity and Related Stockholder Matters               8
Item 6.         Selected Financial Data                                                                 9
Item 7.         Management's Discussion and Analysis of Financial Condition and Results of
                Operations                                                                              9
Item 7A.        Quantitative and Qualitative Disclosures about Market Risk                             12
Item 8.         Financial Statements and Supplementary Data                                            12
Item 9.         Changes in and Disagreements with Accountants on Accounting and Financial
                Disclosure                                                                             21
Item 10.        Directors and Executive Officers of the Registrant                                     21
Item 11.        Executive Compensation                                                                 22
Item 12.        Security Ownership of Certain Beneficial Owners and Management                         22
Item 13.        Certain Relationships and Related Transactions                                         23

Item 14.        Exhibits, Financial Statement Schedules and Reports on Form 8-K                        23

</TABLE>
<PAGE>

               INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

        This annual report on Form 10K includes statements that could be
construed  as  "forward-looking"  in  nature.  For such statements, we claim the
protection  of  the Private Securities Litigation Reform Act of 1995. Readers of
the  Form  10  are  cautioned,  not to place undue reliance on these statements,
which speak only as of the date on which they are made. These statements involve
a  number  of  risks  and  uncertainties,  which  include  statements  about the
Company's  strategy  and  goals,  and  other  statements that are not historical
facts.  Some  of  the  statements  are  preceded by the words "intends," "will,"
"plans,"  "expects,"  "anticipates,"  "estimates,"  "aims,"  and  "believes"  or
similar words. The Company undertakes no obligation to update publicly or revise
any of these statements. Actual events or results may differ materially from the
Company's  expectations.  Important  factors  that could cause actual results to
differ materially from those stated or implied by any statement include, but are
not  limited  to,  the  following:  the ability to complete, if at all, within a
reasonable  time  period;  future  quarterly  or  annual  financial results; the
timing,  success  and  cost  of  research  and  development,  and  out-licensing
endeavors.

ITEM 1.  BUSINESS.

     GENERAL DEVELOPMENT OF BUSINESS.

     Inamco International Corp. ("Inamco",  the "Company",  or "Registrant") was
incorporated  in Delaware on January 17, 1993  originally  as Omni Assets,  Inc.
("Omni).  Omni, at the time of its  inception,  was  established to operate as a
financial  consulting  firm, whose clients were to be other companies in need of
assistance  in  raising   capital,   and/or   required  advice  on  mergers  and
acquisitions,  or the hiring of  management.  Since the  Company's  inception in
1993, it has never been an operating concern and/or generated any revenues.

     The Company is a  developmental  stage  corporation as defined in Financial
Accounting  Standards Board Statement No.7, and is a non-operating public shell,
meaning it has not commenced full-scale  operations and has insignificant assets
and  liabilities.  Since its inception,  the Company has not had any revenues or
earnings,  and the future  success of the  Company is  dependent  on  creating a
viable business and/or finding a suitable merger candidate.

     In September of 1999, negotiations between Mr. Varges George, the president
and sole  shareholder of Inamco Services  Corp., a management  company that owns
and  operates  two  separate  and wholly  owned  subsidiary  companies:  Medicos
Laboratories,  Inc. and Advanced  Diagnostics,  Inc.  (descriptions of which are
located elsewhere in this Form-10),  and the directors and majority shareholders
of Omni began.  Initially,  the reasons behind the acquisition of Omni, revolved
around the  possible  merger of Mr.  George's  pharmaceutical  company,  Medicos
Laboratories,  Inc., and Omni (as further described in this Form 10 report). All
immediate collaborations between the parties focused upon an entity, to be owned
by Mr.  George,  successfully  merging  with  Omni.  There  was  also  a  mutual
understanding  between  the  parties  that  Royal  Capital  Corp.  ("Royal"),  a
consulting  company to be retained,  would act as a consultant  and  familiarize
itself with the merger between the two companies.

On October 26, 1999, Inamco  International  Corp., a Delaware  Corporation,
being  incorporated  on the 18th day of  October,  1999,  merged  with Omni in a
transaction solely for stock.  Pursuant to the merger agreement,  1000 shares of
Inamco  were  exchanged  for  22,712,500  shares of Omni.  Once the  merger  was
completed,  Inamco terminated its corporate  existence and, in February of 2000,
the name of Omni Assets,  Inc., was changed to Inamco International Corp. At the
completion of the merger, the Company's common stock had a par value of $.00001,
giving the value of those shares, issued as part of the merger, a worth of $227.

     In October of 1999, a formal  agreement  was entered into with Royal.  This
agreement paid Royal for consultation  services connected with the merger of the
two  companies.  In  consideration  for  those  services,  Inamco  agreed to pay
1,355,365 shares of its restricted common stock to Royal and/or it designees.

     In  January  of  2000, preliminary  steps  were  taken  to  measure  the
feasibility  of  a  merger  and/or  acquisition  of  Medicos  Laboratories, Inc.
("Medicos")  by  Inamco.  Medicos,  at  the time, was a company dedicated to the
research,  development  and  formulating  manufacture  of  quality  generic
pharmaceuticals. Generic pharmaceuticals, as a whole, have the same chemical and
therapeutic  properties  as  their  brand-named counterparts. Although typically
less expensive, they are required to meet the same governmental standards as the
brand-named drug, and most must receive approval from the appropriate regulatory
authority prior to manufacture and sale. A manufacturer cannot produce or market
a  generic  pharmaceutical  until  all  relevant  patents  (and  any  additional
government-mandated market exclusivity periods) covering the original brand-name
product  have  expired.  It  was  later  deemed that Medicos was too much in its
infancy  stage  to  be a realistic merger candidate. Although it was researching
formulations  on  certain  generic  pharmaceuticals,  it did not have all of its
laboratory  equipment,  proper  FDA  and  Good  Manufacturing  Procedures
certification(s),  and/or  any  revenue producing contractual agreements. It was
recommended  that  any  arrangements to merge the two companies be halted, until
such  time,  if  any,  that  Medicos  could  become  an operating pharmaceutical
company.  At  this  time  it  appears  that  a  merger with Medicos is unlikely.

     In February  of  2000,  the Company entered into a collaborative agreement
with  Royal,  so  that  Royal  could  provide  certain  services  to Inamco on a
non-exclusive  and  best  efforts  basis. Royal contracted to familiarize itself
with  the  business  operations,  prospects  and  management of Inamco, and make
certain  recommendations  in  order  to  enhance  the  marketing  of  any future
products. In consideration of the foregoing, Inamco immediately agreed to tender
a  total  of 1,000,000 shares of its common stock to Royal and/or its designees.

     In March of 2000, Inamco began to compensate Royal, as per their
contractual  obligations.  In  the  month  of  March,  Inamco  issued a total of
1,170,000  restricted  common  shares  to  Royal  and/or  their  assigns.

     In May of 2000, Inamco  continued  their  compensation  to  Royal  with  an
additional  issuance  of  1,000,000  shares  of restricted common stock to Royal
and/or  their  assigns.

     In November of 2000,  Inamco  finalized  the  compensation  to Royal with a
final  issuance of 185,365  shares of  restricted  common  stock to Royal and/or
their assigns.

     As of November 2000, the Company had paid out a total of 2,355,365
restricted  common  shares  to  Royal  Capital, and/or their assigns, as per the
parties'  agreements  (a  list  of  Royal's assigns is located elsewhere in this
Form-10).  The  Company  claims no knowledge, as to why Royal decided to issue a
certain  number  of  its  restricted  common shares to certain designees. Inamco
acted  within  the  purview  of  its contractual obligations, and Royal was paid
within the three different time frames as stated above. At the time in which the
agreements  were  signed  between  the parties, the value for the services to be
rendered  by  Royal, to the Company, equaled approximately $750,000 dollars, and
Royal  agreed  to  accept  restricted  shares  of common stock rather than cash.

     The Company then began to initiate certain internal business procedures by
retaining  the services of a lawyer and the consulting services of an investment
banker.  The  Company  agreed  to  issue  25,000 and 68,245 shares of restricted
common  stock,  respectably,  to  each. For legal services rendered, shares were
issued  in  May  of  2000,  and  in  November  of  2000,  shares were issued for
consultation  services  (descriptions of which can be found in other sections of
this  Form-10).

     Since the Company's inception, the ability to achieve and identify certain
goals  or objectives has been dependent upon many factors, some of which are out
of  the Company's control. The ability of the Company to merge with an operating
pharmaceutical  company  will  depend  upon  many  factors,  including  the
identification  of  a  proper  merger  candidate,  the  size  of  any  future
collaborations, the success rate of future marketing strategies, and general and
industry-specific  economic  conditions  which  may  affect  any  and all future
business  expenditures.  As  a  consequence,  the  likelihood  of the Company to
produce  any  revenues  in  the  future  is  dependent solely on a merger and/or
acquisition,  the  success  of  which  may  never  be  achieved.

     At present, the Company has never had any subsidiaries, and is currently
not  the  subject  of,  or  engaged  in, any bankruptcy, receivership or similar
proceedings. There has been no material reclassification, merger, consolidation,
or  any  acquisition  or disposition of any material amount of assets to or from
the  Company,  and  the  Company  has  undergone no structural changes since the
merger  of  Inamco  and Omni. The Company's common stock presently trades on the
over-the-counter  pink  sheets under the symbol IICO.PK and as of July 30, 2003,
the  Company  had  27,600,000  shares outstanding with a last trade bid price of
$0.01.

PLAN OF OPERATION.

     FINANCIAL INFORMATION ABOUT SEGMENTS.  The information required by this
section  calls  for  a  report on each segment, as defined by generally accepted
accounting  principals, revenues from external customers, a measure of profit or
loss  and  total  assets,  as described by Regulation S-K (Subpart 229.101). The
Company  must report this information for each of the last three fiscal years or
for  as  long  as  it  has  been  in  business, whichever period is shorter. The
information  provided  for  in this section does conform with generally accepted
accounting  principals  and is included in, and can be crossed referenced to our
audited  financial  statements.

     NARRATIVE  DESCRIPTION  OF  BUSINESS.  At  present,  the Company has yet to
commence  any  operations,   and  does  not  own  any  intellectual   properties
whatsoever. All future business is hypothetical and predicated on the successful
merger with an established pharmaceutical  manufacturer,  which cannot be relied
upon and/or guaranteed.

If  a  successful  merger  is  to be consummated with an existing pharmaceutical
manufacturer, the proper candidate will need to be an established pharmaceutical
company  that  presently  manufactures  and  distributes  certain  generic
over-the-counter  ("OTC")  and  prescription  drugs.  Current  management of the
Company  has  determined,  that any candidate to be acquired or merged with, may
need  to  have  the  ability  to manufacture generic drugs whose equivalents are
Actifed(R),  Allerest(R), Anacin(R), Co-Tylenol(R), Exlax(R), Sudafed(R), and/or
NightQuil(R).  The candidate should also be in the position to produce other OTC
drugs  and/or  generic  prescription  medications.

If a  merger  and/or acquisition should be consummated, Inamco believes that it
may  be  in  a  position to sell its future products acquired in a the merger to
distributors  (both  domestic  and  international),  hospitals, and large buying
groups.  However,  the Company is not currently in a position to sell its future
products  to  such groups. The Food and Drug Administration ("FDA") oversees the
manufacture  of  both brand-name and generic pharmaceuticals, and the production
of  these  drugs  is  usually  subject  to:

          (1)  An  approved  New  Drug  Application  ("NDA")  which  allows  the
               medication to state both its safety and effectiveness;
          (2)  Marketed under an NDA for safety only;
          (3)  Marketed without an NDA; or
          (4)  Marketed pursuant to over-the-counter monograph regulations.

     For  generic   pharmaceuticals  being  manufactured  for  both  safety  and
effectiveness,  prior  to  marketing,  these  drugs  must  undergo  and  pass an
Abbreviated New Drug Application ("ANDA"). The Company realizes that in order to
get approval from the FDA via an ANDA, all drug product  applications  will need
to  include:  data  relating to product  formulation,  raw  material  suppliers,
stability  information,   manufacturing  techniques,  packaging,  labeling,  and
quality control information. Those drugs subject to an ANDA under the Drug Price
Competition  and Patent Term  Restoration Act of 1984 (the  "Waxman-Hatch  Act")
must  also  contain  bio-equivalency  data.  Generics  can also be  marketed  by
adhering to FDA enforcement  policies, or be subject to an over-the-counter drug
review monograph process.  At present,  Inamco has not prepared or submitted any
ANDA applications;  it is contemplated  however that certain applications may be
submitted  based on certain  drugs that  Inamco may  manufacture  if a merger is
consummated.

     If a successful merger and/or acquisition is consummated,  the Company will
be  immediately   subject  to  the  following  FDA   enforcement   policies  and
over-the-counter  drug review monograph  processes with respect to those certain
generic drugs wished to be manufactured and marketed:

          o    Comply with Standard Operating  Procedures and Good Manufacturing
               Practices which include:
          o    The  development  of a drug  formulation  that  matches the Brand
               product that is to be reproduced (i.e. assay, content uniformity,
               dissolution profiles, and stability)
          o    The manufacture of a pilot batch that will equal 1/10 the size of
               the actual production batch
          o    Test and  validate  both  the  manufacture  process  and the drug
               potency of the pilot batch
          o    Generate  stability data covering a 3 month time frame in which a
               portion  of the  pilot  batch  will be  subjected  to a  constant
               temperature of 40 degrees centigrade and 75% relative humidity
          o    Generate  stability  data  covering  a  long-term  time frame (12
               months) in which a portion of the pilot  batch will be  subjected
               to a  constant  temperature  of 25 degrees  centigrade  and a 60%
               relative humidity
          o    Upon successful stability studies for the 3 month time frame, the
               product  is  ready  for  mass  production  and  marketing  o  The
               manufacture   of  3  production   sized   batches  in  which  the
               manufacture  process as well as drug  potency  will be tested and
               validated
          o    Prepare  and  submit  final   documentation  to  State  Formulary
               committees,  to obtain an  approval  from each  State so that the
               product  may  be  reimbursed  through  insurance   companies  and
               Medicaid.

     After a merger  and/or  acquisition  is  consummated,  and if the candidate
company should not have any business  relationships  with  manufacturers  of raw
chemicals,  or if any relationship is deemed "not being in the best interest" of
Inamco;  the Company will then identify other sourcing chemical  companies where
raw  materials  can be  purchased  in bulk for the  manufacture  of its  generic
pharmaceuticals.  All raw chemicals needed are readily  available;  however,  it
will be the Company's  intention to always be conscious of pricing,  for certain
chemical companies will give discounts when buying in bulk and placing continual
orders.  It will be  Inamco's  expectation  to  benefit  from the fact  that the
pharmaceutical  industry is non-cyclical  and the need for quality generic drugs
is always present.  At present,  Inamco has not identified any sourcing chemical
companies where raw materials could be purchased.  If any company to be acquired
should not have a business  relationship(s)  with a sourcing  chemical  company,
Inamco will begin the  identification  process once a merger is  consummated,  a
course of action that should not take more than one month.

     A proper merger candidate will also have its good manufacturing  procedures
("GMP") certification issued by the FDA. This certification will allow Inamco to
produce certain generic pharmaceuticals to sell to future clientele.  Coinciding
with expected  revenues  generated,  Inamco will submit  several  different ANDA
applications  to the  FDA,  so  that  it may  manufacture  certain  prescription
medication and add considerable  profit  potential to its entire  pharmaceutical
operation.  At present,  Inamco has no clientele or business operations and will
rely on a merger in order to generate future business,  as well as a client list
of wholesalers and distributors.

     It will be Inamco's future intention not to have a single customer or group
of customers  comprising more than 20% of its revenue  stream.  The Company will
continue to add to its client base by tendering  offers  through  certain buying
groups,  municipalities,  government agencies, hospital and retail distributors.
This will ensure  enough of a customer  base, so that the loss of any one client
will not significantly affect the Company's revenue stream.

     Since the Company  has yet to begin any  operations,  it has no  backlogged
orders or government  contracts  subject to  renegotiation  or  termination.  At
present the Company has no competition as well. It is contemplated, however that
if a merger and  acquisition  is successful,  the Company will have  competition
with other  manufacturers  of generic  pharmaceuticals.  These  competitors will
probably have  substantially  greater capital  resources than Inamco, as well as
seasoned sales and marketing teams in place. It is the Company's belief that its
primary   competition   will   come  from   other   manufacturers   of   generic
pharmaceuticals,  brand name pharmaceutical  companies that also produce generic
drugs, the original  manufacturer  of the brand named drug in which the generic
is derived, and brand named pharmaceutical companies that can produce new drugs
for the same malady as the Company's proposed manufactured generic drug.

     Inamco  has  not  spent  any  monies  on  company-sponsored   research  and
development  activities,  and  there  are no plans  to do so in the  foreseeable
future. Once a merger and/or acquisition is consummated,  the Company intends to
be in compliance  with all federal,  state and local  provisions with respect to
the  manufacture  of generic  pharmaceuticals.  The FDA will oversee and enforce
compliance for good manufacturing  practices, and it is the Company's additional
intention  to  locate a  manufacturing  facility  located  in a  properly  zoned
manufacturing area.

RISK FACTORS

RISKS INHERENT IN A DEVELOPMENT STAGE COMPANY. The Company was incorporated
in Delaware on January 17, 1983  originally as Omni Assets,  Inc. On October 26,
1999, Inamco  International  Corp., a Delaware Corporation being incorporated on
the 18th day of  October  1999,  merged  with Omni in a  transaction  solely for
stock. In February of 2000, the name of Omni was changed to Inamco International
Corp. Since the Company's  inception,  it has been engaged almost exclusively in
organizational  activities  and  has  just  recently  begun  the  search  for  a
pharmaceutical  merger  candidate,  so  that  it  may  enter  into  the  generic
pharmaceutical  manufacturing arena. Accordingly,  as a transitional development
stage company, the Company has had no operating history upon which an evaluation
of the Company's  prospects can be determined.  Consequently,  the likelihood of
success of the Company must be considered in view of all of the risks,  expenses
and delays inherent in the establishment of a new business,  including,  but not
being limited to, expenses and delays of an ongoing business that has commenced,
slower than anticipated manufacturing and marketing activities,  the uncertainty
of market assimilation of the Company's product and other unforeseen factors.

         RISKS  RELATING  TO A MERGER.  It must noted that the  Company  has not
identified a suitable  merger  candidate to date,  and no assurance  can be made
that a  candidate  will  ever be found.  Accordingly,  the  likelihood  that the
Company may merge with an ongoing  pharmaceutical  company must be considered in
view of all of the risks,  expenses and delays inherent to a merger,  including,
but not being  limited  to,  expenses,  agreements  and  delays of  merging  one
business  with  another,  due  diligence   compilation,   shareholder  approval,
regulatory  approval,  legal and accounting  reviews,  and any other  unforeseen
factors that are to effect the Company's  ability to merge with a pharmaceutical
concern.

         NO  OPERATING  HISTORY;   LOSSES.  The  Company  has  had  no  business
operations  and no prior operating history. The Company anticipates that it will
continue  to  incur  losses  and  generate  negative cash flow once a merger and
acquisition has been consummated. At this time, the Company has no revenues; and
there  is no assurance that the Company will ever have revenues or be profitable
or  achieve  positive  cash  flow  from  operations.  Since October of 1999, the
Company  has  incurred  a  total  loss  of  $37,243 up and until March 31, 2003.

         DEPENDENCE UPON KEY PERSONNEL.  The success of the Company depends,  in
part, upon the successful performance of its president and secretary, Mr. Varges
George. Mr. George at present is the sole executive and director of the Company.
He has  complete  and  exclusive  control  as to all  aspects  of the  Company's
direction and operation.  The Company had entered into a one year  comprehensive
employment contract with Mr. George dated October 27, 1999. The contract engaged
Mr. George to provide exclusive services to the Company for a total of one year,
and then to render his services from time to time, as per the  discretion of the
Company's  director (Mr. George being that  director).  Although Mr. George owns
another  company,  as described in other  sections of this Form 10, he has never
broken the  exclusivity  clause  between the time frames of October 27, 1999 and
October 26,  2000,  for the reason that he remained  within the  confines of his
employment  agreement,   while  qualifying  and  quantifying  possible  business
acquisition and/or merger.  Mr. George's  compensation was a one-time payment of
one million shares of Inamco  International,  Corp.  common stock (a copy of the
Agreement is attached  hereto).  If a merger and/or  acquisition is consummated,
the Company  intends to elect a board of directors,  who will employ  additional
qualified executives, employees and consultants having significant experience in
delivering the business  expertise needed. In the interim,  if Mr. George should
fail to perform any of the duties undertaken by him, for any reason  whatsoever,
the ability of the Company to find a merger  candidate,  so that  manufacturing,
marketing  and  distribution  of  generic  pharmaceutical  may  begin,  could be
adversely  affected.  The Company may seek in the future to secure and  maintain
key man  insurance on Mr.  George;  there is no  assurance,  however,  that such
insurance  will in fact be obtained.  Moreover,  the Company  believes there are
available  qualified  managerial  and other  personnel in sufficient  numbers to
properly staff the  facilities  and offices of the Company,  but there can be no
assurance  that  the  Company  will  be  able to  attract  sufficient  qualified
personnel.

     REGULATION.  The Company,  as well as all  participants in the generic over
the counter pharmaceutical  industry, must comply with the rules and regulations
of the Food and Drug  Administration.  ("FDA"). The manufacture of generic drugs
is governed by FDA regulations and protocols. Such regulations and protocols are
subject to change.  Therefore,  the Company's  approach to  certification,  if a
merger should occur, may require  modifications to adjust for future  regulatory
change. Furthermore, the Company's future activities (although less intense than
more established pharmaceutical manufacturers who are principally engaged in the
manufacture of controlled drug products) are subject to extensive regulation not
only by the FDA, but comparable state regulatory and foreign health authorities.

     COMPETITION.   If  a  merger   should  occur  between  the  Company  and  a
pharmaceutical  concern, it is the Company's belief that there are manufacturing
entities  that  currently  offer  products and  services  similar to those to be
proposed by the Company. These entities may have greater financial and personnel
resources  than the  Company.  Manufacture  and use of generic  over the counter
("OTC") drugs  throughout the United States is on the increase.  The generic OTC
manufacturing industry, in general, is dominated by a small number of companies,
which are well known to the public.

         THERE IS A POTENTIAL CONFLICT OF INTEREST OF THE COMPANY'S PRESIDENT IF
THE  COMPANY   ACQUIRES  AN   INDEPENDENT   PHARMACEUTICAL   COMPANY  OR  BEGINS
NEGOTIATIONS WITH MEDICOS LABORATORIES,  INC. Mr. Varges George is currently the
president;  and sole  shareholder  of Inamco  Services  Corp.  which is  totally
independent  from,  and should not be confused with Inamco  International  Corp.
This management  company owns and operates two separate wholly owned  subsidiary
companies,  one of  which  is a  generic  pharmaceutical  manufacturer,  Medicos
Laboratories,  Inc.  ("Medicos").  Medicosoperates  primarily  as  a  laboratory
engaged in the development and manufacture of non-prescription  and prescription
generic  drugs.  Among  the  products  being  produced  are:  clinical  chemical
reagents, tablets, chewable tablets, capsules, liquids and powders. It should be
noted  that if Inamco  International  Corp.  should  acquire  and/or  merge with
another pharmaceutical company other than Medicos Laboratories Inc., there would
be a conflict of interest  resulting form Mr. George's 100% ownership in Medicos
and his majority ownership in Inamco  International Corp. The control of both of
these  competing  companies would present a conflict of interest for Mr. George.
If this  should  occur,  it will be the legal  responsibility  of Mr.  George to
properly relinquish one of his executive roles, as well as any equity ownership,
within one of the competing companies.

     POTENTIAL  CONFLICT OF INTEREST REGARDING THE TIME SPENT BETWEEN COMPANIES.
As described  elsewhere in this Form 10, the  Company's  president,  Mr.  Varges
George is  currently  the sole  shareholder  of Medicos  Laboratories,  Inc.,  a
company that manufactures generic pharmaceuticals;  Mr. George was also party to
an exclusive  employment  contract  between he and Inamco from October,  1999 to
October,  2000. Any potential  conflicts of interest regarding Mr. George's time
spent,  with respect to both companies,  is resolved by the fact that Mr. George
has  never  been an  officer  or  employee  of  Medicos  and does not see to the
day-to-day operation of that company.

     INAMCO'S  COMMITMENT  TO  ISSUE  AND REGISTER FOR RESALE A  LARGE  NUMBER
 OF  SHARES  PURSUANT  TOCONTRACTUAL OBLIGATIONS. In October of 1999, a formal
agreement was entered into
with  Royal  Capital,  a  consultation  firm.  This  agreement  paid  Royal  for
consultation  services connected with certain merger activities had between Omni
and Inamco (as described  elsewhere in this Form 10). In consideration for those
services,  Inamco agreed to pay a total of 2,355,365 shares of restricted common
stock to Royal and/or its designees.  As of June 2, 2003,  Inamco had 27,600,000
shares issued and outstanding, inclusive of those restricted shares forwarded to
Royal and/or their  designees.  Therefore,  should Royal and/or their  designees
sell all or a large number of their common  shares,  once all  restrictions  are
lifted,  it could reduce the per-share value of Inamco's common shares currently
traded on the NASDAQ pink sheets and currently held by existing investors.

     EFFECTS ON THE FLUCTUATION OF COSTS AND AVAILABILITY OF RAW MATERIALS. If a
merger is to occur,  the Company intends to purchase premium grade raw materials
for use in its generic drug manufacturing  enterprise.  Such unprocessed natural
products  will  be  obtained   from  third  party   sources  and   manufacturing
sub-contractors.  The price and  availability of these raw materials are subject
to  numerous  factors  not  within  the  Company's  control  including:  weather
conditions,  policies of foreign countries and/or trade  restrictions as well as
the status of the worldwide  demand for generic drug  ingredients.  In the event
the Company cannot timely  acquire its raw materials from third party  entities,
the Company's  ability to ship its products and service to its targeted  markets
on a timely basis, if at all, would be negatively affected.

     RELIANCE  ON OUTSIDE  SUPPLIERS.  After a merger,  the  Company  intends to
purchase its raw materials and supplies from independent sources. It will remain
dependent upon such outside sources for all of its unprocessed natural products.
There  can be no assurance that these sources will be able to provide adequately
for  the  future  needs  to  the Company. In the event that any of the Company's
future  suppliers  should suffer quality control problems, lack of raw materials
or  financial  difficulties,  the  Company would be required to find alternative
sources  for its product lines. The Company believes that the likelihood that it
could  identify  a  broad base of alternative sources is high based on the large
number  of  easily  accessible and affordable producers of compounds for generic
drugs  in  the manufacturing marketplace. The time lost in seeking and acquiring
additional  and  newer  sources,  however  could  adversely affect the Company's
future  revenues  and  profitability.

     PRODUCT   LIABILITY.   The   testing,   marketing   and  sale  of   generic
pharmaceuticals entail an inherent risk of allegations of product liability, and
there can be no  assurance  that product  liability  claims will not be asserted
against the Company.  Inamco may incur product  liability due to product failure
or improper use of products by the user.  The Company  intends to obtain product
liability insurance that should be adequate for future operations.  There can be
no assurance,  however,  that the amount of insurance,  once  obtained,  will be
sufficient to fully insure  against claims that may be made against the Company.
At present,  the Company has not prepared or submitted any  applications  to the
Food and Drug Administration with respect to testing,  marketing, or the sale of
generic  pharmaceuticals;  it is contemplated  however that certain applications
may be submitted based on certain drugs that the Company may manufacture  once a
merger is consummated. Once applications are submitted, the Company cannot state
when approvals will be had, if ever.

         THE GENERIC DRUG  ENFORCEMENT ACT OF 1992. Which was amended to the FDC
Act,  gives the FDA six ways to penalize any entity that  engages in  wrongdoing
with respect to the  development  and/or  manufacture  of a generic drug, or the
purposefully  faulty  submission of an ANDA, which include,  but are not limited
to:

          1)   Permanently  or  temporarily  prohibit  alleged  wrongdoers  from
               submitting or assisting in the submission of an ANDA;
          2)   Temporarily  deny approval of, or suspend  applications to market
               particular generic drugs;
          3)   Suspend  the  distribution  of all drugs  approved  or  developed
               pursuant to an invalid ANDA;
          4)   Withdraw approval of an ANDA;
          5)   Seek civil penalties; and/or
          6)   Significantly  delay the  approval of any  pending  ANDA from the
               same party.

At present,  the Company has never been the subject of any enforcement action by
the FDA (and/or otherwise),  and it is the intention of the Company to acquire a
pharmaceutical  entity that itself has had no  previous  problems  with the FDA.
There can be no assurances,  however, that restrictions and/or fines will not be
imposed on Inamco in the future.

ITEM 2. PROPERTIES.

        At present, the Company does not own any property, or is a part of any
long-term lease agreements.

ITEM 3. LEGAL PROCEEDINGS.

        None.

ITEM 4. SUBMISSIONS OF MATTERS TO A VOTE OF SECURITY HOLDERS.

        No matters were submitted to a vote of security holders during the
fourth quarter of the fiscal year covered by this report.

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS.

        Our common stock has traded on the Nasdaq Pink Sheets under the symbol
"IICO.PK" The following table sets forth, for the period indicated, the high and
low bid quotations for the common stock as reported by the Nasdaq Pink Sheets.

                                                              HIGH      LOW
                                                            --------  --------
                    Year ended December 31, 2001
Third Quarter (from July 28, 2000)                          $    .08  $    .05
Fourth Quarter                                              $    .05  $    .05

                                                              HIGH      LOW
                                                            --------  --------
                    Year ended December 31, 2002
First Quarter                                               $    .05  $    .01
Second Quarter                                              $    .01  $    .01
Third Quarter                                               $    .01  $    .01
Fourth Quarter                                              $    .01  $    .01


        On July 30, 2003, the last reported sale price on the Nasdaq pink
Sheets for our common stock was $0.01 per share.

        As of July 30, 2003 there were approximately 50 stockholders of
record of the Company's common stock.

DIVIDENDS

        We have never declared or paid any cash dividends on our capital stock
and do not anticipate paying any cash dividends in the foreseeable future.

USE OF PROCEEDS FROM THE SALE OF REGISTERED SECURITIES

       The Company has not recorded and/or sold any registered securities for
the year ending December 31, 2002.


ITEM 6. SELECTED FINANCIAL DATA.

        Reference is made to Selected Financial Data in "Item 8. Financial
Statements and Supplementary Data" included elsewhere in this Annual Report
Form 10k.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.


        You should read the following discussion and analysis in conjunction
with the Company's "Financial Statements and Supplementary Data" included
elsewhere in this Form 10k.


        At present, the Company has yet to commence any operations, and does not
own any intellectual properties whatsoever. The Company is in the development
stage as defined in Financial Accounting Standards Board Statement No.7, and is
a non-operating public shell, meaning it has not commenced full-scale operations
and has insignificant assets and liabilities. Since its inception, the Company
has not had any revenues or earnings, and all future business is hypothetical
and predicated on the successful merger with an established pharmaceutical
manufacturer.


CRITICAL ACCOUNTING POLICIES AND MANAGEMENT ESTIMATES


        It cannot be assured that the Company will have any accounting policies
and/or management estimates, based off of actual business operations, in the
foreseeable future. The initiation of these practices will only begin once a
successful merger with an established pharmaceutical manufacturer has been had.
However, the Securities and Exchange Commission defines critical accounting
policies as those that are, in management's view, most important to the
portrayal of the company's financial condition and results of operations and
most demanding of their judgment. Our discussion and analysis of our financial
condition and results of operations are based upon our consolidated financial
statements, which have been prepared in accordance with accounting principles
generally accepted in the US. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses. We base our estimates upon
historical experience and on various other assumptions that are believed to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions. If the Company should merge
with an existing pharmaceutical company, our accounting policies will include:

        Revenue Recognition. Our revenue recognition policies will be in
accordance with the Securities and Exchange Commission Staff Accounting Bulletin
(SAB) 101, Revenue Recognition in Financial Statements. SAB 101 provides
guidance related to revenue recognition based on the interpretations and
practices developed by the Securities and Exchange Commission. Some of our
future pharmaceutical manufacturing agreements may contain multiple elements,
including "downstream milestones" and royalty obligations.


        If revenues are to occur from "milestones", cash flow is recognized when
earned, as evidenced by written acknowledgment from our collaborator, provided
that (i) the milestone event is substantive and its achievability was not
reasonably assured at the inception of the agreement, and (ii) our performance
obligations after the milestone achievement will continue to be funded by our
collaborator at a comparable level to, or before the milestone achievement. If
both of these criteria are not met, the milestone payment can be recognized over
the remaining minimum period of our performance obligations under the agreement.
If upfront fees are to be negotiated in any future contracts, they can be
recognized over a period of time relative to the services to be provided.

        Goodwill and Intangibles. Purchase accounting requires accounting
estimates and judgments to allocate the purchase price of any future acquisition
to the fair market value of the assets and liabilities purchased. Any future
acquired technology can be amortized over its useful life. The estimated useful
life can be determined based on an analysis, as of any acquisition date, of
conditions in, and the economic outlook for, the pharmaceutical industries and
the patent life of that specific technology. As with any intangible asset, we
will evaluate the value of the technology and, if necessary, we will have a
future write-down of the carrying value of the technology. If it should be
determined that any technology has become impaired, that may accelerate the
amortization of any technology if it should be deemed that its life has been
shortened.


        Income Taxes. At present, the Company has yet to commence any
operations, and does not own any intellectual properties whatsoever. Since its
inception, the Company has not had any revenues or earnings however, it is
contemplated that once business operations begin, we could record a valuation
allowance, in order to reduce our deferred tax assets. More consideration on
future taxable income and feasible tax planning strategies in assessing the need
for a valuation allowance will be had once a successful merger is completed.


        The above is not intended to be a comprehensive list of all or any of
our present or future accounting policies. In many cases, the accounting
treatment of a particular transaction is specifically dictated by generally
accepted accounting principles, with no need for management's judgment in their
application. There are also areas in which management's judgment in selecting
any available alternative would not produce a materially different result. See
our audited consolidated financial statements and notes thereto in this Report
on Form 10k which contain accounting policies and other disclosures required by
generally accepted accounting principles.


YEAR ENDED DECEMBER 31, 2002 COMPARED TO THE YEAR ENDED DECEMBER 31, 2001


        Revenues. We recorded no revenues for this time frame, and you should
read the following in conjunction with the Company's "Financial Statements and
Supplementary Data" included elsewhere in this Form 10k.


        Research and Development Expenses. There has been no Research and
development expenses, and the following should be read with the Company's
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

        General and Administrative Expenses. General and administrative expenses
increased $8,701 to $9,226 for the year ended December 31, 2002 from $525 for
the year ended December 31, 2001. The increase was a result of general and
administrative expenses for Inamco, which consisted primarily of professional
fees and other general corporate expenses. We expect that our general and
administrative expenses will increase to support our growth and requirements as
a public company.


        Amortization of Deferred Compensation. There has been no Amortization of
Deferred Compensation for the Company, and the following should be read with the
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

        Interest Income. Interest income was nominal for the year ended December
31, 2002 and the year ended December 31, 2001. This was due to a nominal cash
balance that did not exceed $950, at any given time, within the Company's
primary corporate account.


        Interest Expense. Interest expense was nominal for the year ended
December 31, 2002 and the year ended December 31, 2001. This was due to a
nominal cash balance that did not exceed $950, at any given time, within the
Company's primary corporate account.


        Gain on Investment. We recorded no Gains on Investment for this time
frame, for the Company does not own any long-term or short-term liquid financial
instruments, and you should read the following in conjunction with the Company's
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

        Other Income. We reported no Other Income for this time frame, and you
should read the following in conjunction with the Company's "Financial
Statements and Supplementary Data" included elsewhere in this Form 10k.

        Non-Cash Preferred Stock Charge. We recorded no non-cash preferred stock
charge for this time frame, and you should read the following in conjunction
with the Company's "Financial Statements and Supplementary Data" included
elsewhere in this Form 10k.


YEAR ENDED DECEMBER 31, 2001 COMPARED TO THE YEAR ENDED DECEMBER 31, 2000


         Revenues. We recorded no revenues for this time frame, and you should
read the following in conjunction with the Company's "Financial Statements and
Supplementary Data" included elsewhere in this Form 10k.

        Research and Development Expenses. There has been no Research and
development expenses, and the following should be read with the Company's
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

        General and Administrative Expenses. General and administrative expenses
decreased $11,847 to $525 for the year ended December 31, 2001 from $12,372 for
the year ended December 31, 2000. The decrease was a result of the completion of
the merger as explained in other sections of this Form 10k. General and
administrative expenses for Inamco consist primarily of professional fees and
other general corporate expenses. We expect that our general and administrative
expenses will increase to support our growth and requirements as a public
company.

        Amortization of Deferred Compensation. There has been no Amortization of
Deferred Compensation for the Company, and the following should be read with the
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

        Interest Income. Interest income was nominal for the year ended December
31, 2001 and the year ended December 31, 2000. This was due to a nominal cash
balance that did not exceed $350, at any given time, within the Company's
primary corporate account.


        Interest Expense. Interest expense was nominal for the year ended
December 31, 2001 and the year ended December 31, 2000. This was due to a
nominal cash balance that did not exceed $350, at any given time, within the
Company's primary corporate account.


        Gain on Investment. We recorded no Gains on Investment for this time
frame, for the Company does not own any long-term or short-term liquid financial
instruments, and you should read the following in conjunction with the Company's
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

        Other Income. We reported no Other Income for this time frame, and you
should read the following in conjunction with the Company's "Financial
Statements and Supplementary Data" included elsewhere in this Form 10k.

        Non-Cash Preferred Stock Charge. We recorded no non-cash preferred stock
charge for this time frame, and you should read the following in conjunction
with the Company's "Financial Statements and Supplementary Data" included
elsewhere in this Form 10k.


LIQUIDITY AND CAPITAL RESOURCES


        Liquidity refers to our ability to generate adequate amounts of cash to
meet our needs. We have been generating the cash necessary to fund our
operations from continual loans from the president and chief operating officer
of the Company, Mr. Varges George. We have incurred a loss in each year since
inception, and we expect to incur substantial losses for at least the next
several years. We expect that losses may fluctuate, and that such fluctuations
may be substantial. As of December 31, 2002, we had an accumulated deficit of
$35,624. Our accumulated deficit is the result of expenses incurred in
connection with our general and administrative costs, as well as the cost to
support the growth and requirements as a public company.


        Potential immediate sources of liquidity are the continual loans from
Mr. George. Another potential source of liquidity is the sale of restricted
shares of our common stock.


        As of December 31, 2002, we had $927 in cash compared to $38 in cash as
of December 31, 2001. The increase of $889 is primarily attributable to loans
provided for by the Company's president.


        Net cash used in operating activities was approximately $9,226 during
the year ended December 31, 2002. The primary use of cash for the year ended
December 31, 2002 was to fund general and administrative costs, as well as the
cost to support the growth and requirements as a public company. Our net loss in
the period, adjusted for non-cash expenses, amortization, and changes in
operating assets and liabilities. Net cash used in operating activities was
approximately $525 during the year ended December 31, 2001.

        Net cash provided by loans from Mr. George was approximately $9,226
during the year ended December 31, 2002. Net cash proceeds from loans by Mr.
George were $525 during the year ended December 31, 2001.


        Since the Company is in the development stage as defined in Financial
Accounting Standards Board Statement No.7, and is a non-operating public shell,
meaning it has not commenced full-scale operations and has insignificant assets
and liabilities, we presently share an address with Inamco Services, Corp. At
present, the Company has no lease and pays no rent; our address is 801 Montrose
Avenue, South Plainfield, New Jersey, 07080.


        Based on the possibility of a merger between Inamco and a pharmaceutical
company, we would expect to hire between 35 to 50 employees, primarily research
scientists and development staff. This is based off of the average industry
standard for a generic pharmaceutical company and the amount of employees that
they employ. While we believe that our current capital resources and anticipated
cash flows from a merger will not be sufficient to meet any future capital
requirements, we understand that additional financing will be needed. The
estimated length of time current cash and available borrowings will sustain our
operations is based on estimates and assumptions we have made. These estimates
and assumptions are subject to change at any time. We cannot assure you that
adequate funding will be available to us or, if available, that such funding
will be available on acceptable terms. Any shortfall in funding could result in
the curtailment of any merger activities.


INCOME TAXES


        As of December 31, 2002, we had approximately $9,226 of net operating
losses for federal income tax purposes. These amounts reflect different
treatment of expenses for tax reporting than is used for financial reporting.
United States tax law contains provisions that may limit our ability to use net
operating losses in any year, or if there has been a significant ownership
change. Any future significant ownership change may limit the use of our net
operating losses.


ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

         The Company is not exposed to any market risk due to the fact that it
does not own any risk sensitive instruments; all cash is used solely for the
purpose of maintaining a minimum balance within a corporate bank account and the
fluctuations that interest rates play on that cash is immaterial.


ITEM 8. FINANCIAL STATEMENTS.

<TABLE>
<CAPTION>

                           INAMCO INTERNATIONAL CORP.
                          INDEX TO FINANCIAL STATEMENTS
                                                                               PAGE
                                                                               ----

<S>                                                                              <C>
Report of Kahn Boyd Levychin & Company, Independent Auditors
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Stockholders' Equity (Deficit)
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
</TABLE>


<PAGE>

INAMCO INTERNATIONAL CORP.
(A DEVELOPMENT STAGE COMPANY)

YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000




Report of Independent Certified Public Accountants     F1


Financial Statements:

     Balance Sheets                                    F2

     Statements of Operations                          F3

     Statements of Cash Flows                          F4

     Statements of Stockholders' Deficiency            F5

Notes to Financial Statements                         F6-F7






                                       -F-

<PAGE>





               REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
               --------------------------------------------------


BOARD  OF  DIRECTORS  AND  STOCKHOLDERS
INAMCO  INTERNATIONAL  CORP.

We  have audited the accompanying balance sheet of INAMCO INTERNATIONAL CORP. (A
Development  Stage  Company)  as  of  December  31, 2002, 2001 and 2000, and the
related  statements  of operations, stockholders' equity, and cash flows for the
years  then  ended.  These  financial  statements  are the responsibility of the
Company's  management.  Our  responsibility  is  to  express an opinion on these
financial  statements  based  on  our  audit.

We  conducted our audit in accordance with auditing standards generally accepted
in  the  United  States  of  America.  Those  standards require that we plan and
perform  the  audit  to  obtain reasonable assurance about whether the financial
statements  are free of material misstatement. An audit includes examining, on a
test  basis,  evidence  supporting  the amounts and disclosures in the financial
statements.  An audit also includes assessing the accounting principles used and
significant  estimates  made  by  management,  as well as evaluating the overall
financial  statement  presentation.  We  believe  that  our  audit  provides  a
reasonable  basis  for  our  opinion.

In  our  opinion,  the financial statements referred to above present fairly, in
all  material respects, the financial position of INAMCO INTERNATIONAL CORP., as
of  December  31, 2002, 2001 and 2000, and the results of its operations and its
cash  flows  for  the  years then ended in conformity with accounting principles
generally  accepted  in  the  United  States  of  America.

The  accompanying  financial  statements  have  been  prepared assuming that the
Company  will  continue  as  a  going  concern.  As  discussed  in Note A to the
financial  statements,  the Company had a loss from operations and has a working
capital deficiency, raising substantial doubt about its ability to continue as a
going concern.  Management's plans in regard to these matters are also described
in  Note  A. The financial statements do not include any adjustments relating to
the  recoverability  and classification of asset carrying amounts or the amounts
and  classifications  of  liabilities  that  might  result should the Company be
unable  to  continue  as  a  going  concern.




KAHN  BOYD  LEVYCHIN,  LLP

New  York,  New  York
March  31,  2003





                                      -F1-

<PAGE>

 INAMCO INTERNATIONAL CORP.
 (A DEVELOPMENT STAGE COMPANY)
 BALANCE SHEETS
 December 31, 2001, 2002 and 2000

<TABLE>
<CAPTION>
                                                                December 31,
                                                               ------------
                                                      2002         2001       2000
                                                      -----       -----       ----
<S>                                                 <C>         <C>         <C>
ASSETS
     Current Assets
           Cash                                     $    927    $     38    $    343
                                                    --------    --------    --------
                 Total Current Assets                    927          38         343
     Other Assets                                        213         213         213
                                                    --------    --------    --------
                 Total Assets                       $  1,140    $    251    $    556
                                                    ========    ========    ========


LIABILITIES AND STOCKHOLDERS' DEFICIENCY

LIABILITIES
     Current Liabilities
           Accounts payable and accrued expenses    $  5,615    $  1,668    $  1,148
                                                    --------    --------    --------
                 Total Current Liabilities             5,615       1,668       1,148
     Due to Officer/Shareholder                        8,069       1,900       2,200
                                                    --------    --------    --------
                 Total Liabilities                    13,684       3,568       3,348

STOCKHOLDERS' DEFICIENCY
     Common Stock, $.00001 par value
           Authorized: 50,000,000 shares
           Issued and Outstanding: 27,600,000            276         276         276
     Additional paid-in capital                       22,804      22,804      22,804
     Deficit Accumulated in the Development Stage    (35,624)    (26,397)    (25,872)
                                                    --------    --------    --------
                 Total Shareholders' Deficiency      (12,544)     (3,317)     (2,792)
                                                    --------    --------    --------
                                                    $  1,140    $    251    $    556
                                                    ========    ========    ========


</TABLE>

          THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
                                      -F2-
<PAGE>
 INAMCO INTERNATIONAL CORP.
 (A DEVELOPMENT STAGE COMPANY)
 STATEMENTS OF OPERATIONS
 Years Ended December 31, 2002, 2001 and 2000

<TABLE>
<CAPTION>

                                                     Inception
                                                 January 17, 1993 to          Year Ended December 31,
                                                                              -----------------------
                                                 December 31,2002        2002            2001            2000
                                                 ----------------        ----            ----            ----
<S>                                              <C>                 <C>             <C>             <C>
Net Sales                                        $              -    $          -    $          -    $          -
Cost of Goods Sold                                              -               -               -               -
                                                 ----------------    ------------    ------------    ------------
      Gross Profit                                              -               -               -               -

Costs and Expenses
      Bank Charges and Miscellaneous                        2,967           1,226             525           1,215
      Professional and Consulting Fees                     32,657           8,000               -          11,157
                                                 ----------------    ------------    ------------    ------------
                                                           35,624           9,226             525          12,372
                                                 ----------------    ------------    ------------    ------------

Net Loss                                         $        (35,624)   $     (9,226)   $       (525)   $    (12,372)
                                                 ================    ============    ============    ============

Weighted Avereage Number of Shares Outstanding          9,323,472      27,600,000      27,600,000      25,871,020
                                                 ----------------    ------------    ------------    ------------

Loss Per Share                            (A)    $         (0.00)    $      (0.00)   $      (0.00)   $     (0.00)
                                                 ================    ============    ============    ============

      (A) Loss per share less that $.01

</TABLE>


          THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
                                      -F3-
<PAGE>
 INAMCO INTERNATIONAL CORP.
 (A DEVELOPMENT STAGE COMPANY)
 STATEMENTS OF CASH FLOWS
 December 31, 2001 and 2000
<TABLE>
<CAPTION>

                                                                  Inception
                                                              January 17, 1993 to       Year Ended December 31,
                                                                                        -----------------------
                                                               December 31,2002       2002        2001       2000
                                                              ------------------      ----        ----        ----
<S>                                                           <C>                   <C>         <C>         <C>
Cash flows from operating activities:
      Net loss                                                $          (35,624)   $ (9,226)   $   (525)   $(12,372)
      Adjustments to reconcile net loss to net cash used in
      operating activities
          Change in accrued expenses                                       5,615       3,947         520       1,148
                                                              ------------------    --------    --------    --------
                     Net cash used for operating activities              (30,009)     (5,279)         (5)    (11,224)
                                                              ------------------    --------    --------    --------
Cash flows from investing activities:
      Change in other assets                                                (213)          -           -        (213)
                                                              ------------------    --------    --------    --------
                     Net cash used for investing activities                 (213)          -           -        (213)
                                                              ------------------    --------    --------    --------
Cash flows from financing activities:
      Loans from officer/shareholder, net of repayments                    8,068       6,168        (300)      2,200
      Restricted common stock issued in payment of expenses               22,868           -           -       9,367
      Issuance of restricted common stock in connection
      with merger agreement                                                  213           -           -         213
                                                              ------------------    --------    --------    --------
                     Net cash provided by financing activities            31,149       6,168        (300)     11,780
                                                              ------------------    --------    --------    --------
              NET INCREASE (DECREASE) IN CASH                                927         889        (305)        343
      Cash at beginning of period                                              -          38         343           -
                                                              ------------------    --------    --------    --------

      Cash at end of period                                   $              927    $    927    $     38    $    343
                                                              ==================    ========    ========    ========
</TABLE>



          THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
                                      -F4-
<PAGE>
 INAMCO INTERNATIONAL CORP.
 (A DEVELOPMENT STAGE COMPANY)
 STATEMENTS OF STOCKHOLDERS' EQUITY
 Inception January 17, 1993 to December 31, 2002
<TABLE>
<CAPTION>
                                                                                             Deficit
                                                                                            Accumulated
                                                                              Additional      in the
                                              Common Stock $.00001 Par Value     Paid-In   Development
                                                       Shares     Amount        Capital        Stage        Total
                                                   ----------   ----------    ---------    ----------    ----------
<S>                                                   <C>       <C>           <C>          <C>           <C>
Issuance of restricted common stock for services      437,500   $        4    $   1,996    $        -    $    2,000
Net Loss for the year ended December 31, 1983               -            -            -        (2,000)       (2,000)
                                                   ----------   ----------    ---------    ----------    ----------

        Balance at December 31, 1983                  437,500            4        1,996        (2,000)            -
Issuance of restricted common stock for services    1,850,000           19       11,481        11,500
Net Loss for the year ended December 31, 1997               -            -            -        (11,500      (11,500)
                                                   ----------   ----------    ---------    ----------    ----------

        Balance at December 31, 1997                2,287,500           23       13,477       (13,500)            -
Net Loss for the year ended December 31, 1998               -            -            -             -             -
                                                   ----------   ----------    ---------    ----------    ----------

        Balance at December 31, 1998                2,287,500           23       13,477       (13,500)            -
Net Loss for the year ended December 31, 1999               -            -            -             -             -
                                                   ----------   ----------    ---------    ----------    ----------

        Balance at December 31, 1999                2,287,500           23       13,477       (13,500)            -

Net Loss for the year ended December 31, 2000               -            -            -       (12,372)      (12,372)
Issuance of restricted common stock for services    2,600,000           26        9,327             -         9,353
Issuance of restricted common stock in
connection with agreement                          22,712,500          227            -             -           227
                                                   ----------   ----------    ---------    ----------    ----------

        Balance at December 31, 2000               27,600,000          276       22,804       (25,872)       (2,792)
Net Loss for the year ended December 31, 2001               -            -            -          (525)         (525)
                                                   ----------   ----------    ---------    ----------    ----------

        Balance at December 31, 2001               27,600,000          276       22,804       (26,397)       (3,317)
Net Loss for the year ended December 31, 2002               -            -            -        (9,227)       (9,227)
                                                   ----------   ----------    ---------    ----------    ----------

        Balance at December 31, 2002               27,600,000   $      276     $ 22,804    $ (35,624)    $  (12,544)
                                                   ==========   ==========    =========    ==========    ==========
</TABLE>

          THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
                                      -F5-

<PAGE>
INAMCO INTERNATIONAL CORP.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
Years Ended December 31, 2002, 2001 and 2000


NOTE A - ORGANIZATION AND BASIS OF PREPARATION

Inamco  International  Corp.  ("the  Company")  was  incorporated in Delaware on
January  17, 1983 originally as Omni Assets, Inc. ("Omni"). On October 26, 1999,
Inamco  International Corp. ("Inamco"), a Delaware corporation, merged with Omni
in  a  transaction  solely  for  stock.  Pursuant to the merger agreement, 1,000
shares  of  the  original  Inamco  were exchanged for 22,712,500 shares of Omni,
Inamco  terminated  its  corporate  existence and, in February 2000, the name of
Omni  was  changed  to  Inamco  International  Corp.

The Company's financial statements have been presented on a going concern basis,
which contemplates the realization of assets and the satisfaction of liabilities
in  the  normal  course  of business.  The Company has no significant assets, no
revenues  and  has  had  losses  since inception.  The Company can only become a
viable  going  concern  if  it  obtains additional capital and acquires a viable
operating  company.


NOTE  B  -  SUMMARY  OF  ACCOUNTING  POLICIES

A  summary  of  the  significant accounting policies consistently applied in the
preparation  of  the  accompanying  financial  statements  follows.

1.  BASIS OF ACCOUNTING

Financial statements are prepared on the accrual basis of accounting.

2.  USE OF ESTIMATES

In  preparing  financial  statements  in  conformity  with accounting principles
generally  accepted  in  the United States of America, management is required to
make  estimates  and  assumptions that affect the reported amounts of assets and
liabilities  and the disclosure of contingent assets and liabilities at the date
of  the  financial  statements  and  revenues  and expenses during the reporting
period.  Actual  results  could  differ  from  those  estimates.

3.  CASH  AND  CASH  EQUIVALENTS

The  Company  considers  all  highly  liquid investments purchased with original
maturities  of  three  months  or  less  to  be  cash  equivalents.

4.  INCOME TAXES

The  Company  accounts  for  income  taxes  under the provisions of Statement of
Financial  Accounting  Standards  No.  109,  Accounting  for  Income Taxes. This
statement  requires,  among  other  things,  an asset and liability approach for
financial  accounting  and  reporting of deferred income taxes. In addition, the
deferred  tax  liabilities and assets are required to be adjusted for the effect
of  any future changes in the tax law or rates. Deferred income taxes arise from
temporary  differences  resulting  in  the  basis  of assets and liabilities for
financial  reporting  and income tax purposes. A valuation allowance is provided
if  the  Company  is  uncertain  as  to  the realization of deferred tax assets.

                                      F-6
<PAGE>
INAMCO INTERNATIONAL CORP.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
Years Ended December 31, 2002, 2001 and 2000

5.  LOSS PER SHARE

Statement of Financial Accounting Standards No. 128 (SFAS No. 128), Earnings per
Share,  specifies  the computation, presentation and disclosure requirements for
earnings  per  share  for  entities with publicly held common stock or potential
common  stock.

Net  loss per common share - basic and diluted is determined by dividing the net
loss  by  the  weighted  average  number  of shares of common stock outstanding.

NOTE C - DEVELOPMENT STAGE COMPANY

The  Company  is  in  the  development  stage as defined in Financial Accounting
Standards  Board Statement No. 7. It has not commenced full scale operations and
has  insignificant  assets and liabilities. Since inception, the Company did not
have any revenues or earnings. The future success of the Company is dependent on
obtaining a viable business opportunity and /or merger candidate. The Company is
seeking  a  merger  candidate  who  manufactures and distributes certain generic
over-the-counter  drugs.  Management is seeking additional investment capital to
support  its  entrance  into  a  new  business  opportunity  or  merger.

NOTE D - RELATED PARTY TRANSACTIONS

1.  DUE TO OFFICER/SHAREHOLDER

Since  the  merger  in  1999, Varges George, President and majority shareholder,
loaned  the  Company  $8,068  ($2,800 in 2000 and $6,168 in 2002) for payment of
operating  expenses.  The  Company  has paid back $900 ($600 in 2000 and $300 in
2001)  leaving  a  balance  of  $8,068  at  December  31,  2002.

NOTE E - INCOME TAXES

Temporary  differences  and  carryforwards  give rise to deferred tax assets and
liabilities.  The  principal components of the deferred tax assets relate to net
operating  loss  carryforwards.  At December 31, 2002, the Federal net operating
loss  carryforwards  were  approximately  $36,000.  The  net  operating  loss
carryforwards  expire  at  various  dates  through  2022,  and  because  of  the
uncertainty  in  the  Company's  ability  to  utilize  the  net  operating  loss
carryforwards,  a  full  valuation  allowance was provided at December 31, 2002,
2001  and  2000.  Corporate  income  tax returns have not been filed since 1999.

                                      F-7
<PAGE>

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.

        During the acquisition of Omni Assets by the Company, Sobel & Co.,  LLC
acted as the Omni Asset's  certified  public  accounts.  They provided, to the
Company, at that time, audited balance sheets, related statements of operations,
stockholders'  deficiency  and cash flow  statements for the year ended December
31, 1999. Since that time, the Company has had no assets, liabilities, operating
activities,  or revenue and has no need to employ the services of an accountant.
Prior  reports  from the  auditors  did  contain  an  opinion as it relates to a
"Development  Stage"  company and its ability to operate  being  dependent  upon
obtaining a viable and successful  business  opportunity.  The disclaimer of the
opinion  was not  qualified  or  modified  as to  uncertainty,  audit  scope  or
accounting principles except for a modification that describes substantial doubt
surrounding the Company's ability to continue as a going concern.

         The  audited  financial  statements  that  accompany  this Form 10k, as
amended,  were  performed by the Company's  new  auditors,  Kahn Boyd Levychin &
Company,  after Sobel & Co. resigned in October of 2002,  pursuant to Regulation
S-K. A letter that addresses Sobel & Co. resignation is attached hereto.

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.

     IDENTIFICATION OF DIRECTORS.

     At present, Inamco has only one director, Mr. Varges George.

     IDENTIFICATION OF EXECUTIVE OFFICERS.

     At  present,  Mr.  Varges  George,  age 45,  is the sole  executive  to the
Company. He serves in the capacity of both president and secretary.  He has been
the sole executive of the Company since the acquisition of Omni Assets,  Inc. by
the Company on October 26, 1999. At present,  Mr. George has no  arrangements or
understandings  between he and any other  parties  with  respect to the  Company
except those that are stated herein.

     IDENTIFICATION OF CERTAIN SIGNIFICANT EMPLOYEES.

     At present, the Company has no employees or understanding with any
persons acting as production  managers,  sales managers,  or research scientists
who are in any way associated with Inamco.

     FAMILY RELATIONSHIPS.

     There are no relationships between family members of the sole executive and
the Company.

     BUSINESS EXPERIENCE.

     For the past 10 years,  Mr. Varges George has been the president;  and sole
shareholder  of  Inamco  Services  Corp.,  a  management  company  that owns and
operates two separate and distinct  companies:  Medicos  Laboratories,  Inc. and
Advanced Diagnostics, Inc., descriptions of which are as follows:

     MEDICOS  LABORATORIES,  Inc. operates  primarily as a laboratory engaged in
the development and manufacture of  non-prescription  and  prescription  generic
drugs.  As stated earlier in the Form 10, generic  pharmaceuticals,  as a whole,
have  the  same  chemical  and  therapeutic   properties  as  their  brand-named
counterparts.  Although typically less expensive,  they are required to meet the
same  governmental  standards  as the  brand-named  drug,  and most must receive
approval from the  appropriate  regulatory  authority  prior to manufacture  and
sale. A manufacturer cannot produce or market a generic pharmaceutical until all
relevant  patents (and any  additional  government-mandated  market  exclusivity
periods) covering the original brand-name product have expired.  Medicos,  being
an U.S. Food and Drug  Administration  ("FDA")  approved  manufacturer,  has the
ability to produces  both  over-the-counter  ("OTC")  and  certain  prescription
medications in the forms of tablets and capsules. Medicos, in September of 2002,
received FDA approval to manufacture and sell Phenazopyridine tablets, it's sole
product,  and is now  researching  and  developing  other niche drug products in
which to produce and distribute.  An acquisition has not occurred,  for the fact
that Medicos needs to complete certain other business activities,  including but
not  being  limited  to,  final  construction  of  warehousing  areas,  and  the
completion and  consummation  of certain other  manufacturing  and  distributing
agreements.  The Company  anticipates  that an  acquisition  of Medicos could be
consummated  by the end of the third quarter of 2003,  however there are certain
risks, as explained in other sections of this Form 10, associated to merging the
Company  and  Medicos,  which  could  curtail  and/or  suspend  any  acquisition
contemplated.  Readers  of  this  Form  10  report  are  not to  assume  that an
acquisition of Medicos is a likely event.

     ADVANCED  DIAGNOSTICS,  INC. is dedicated to the research,  development and
manufacturing,  and  marketing of  diagnostic  test kits.  The company sells its
products through  wholesalers,  private label  distributors,  drug chain stores,
health maintenance  organizations ("HMO's"),  hospital buying groups, and local,
state and federal government  agencies.  This company produces such products as:
pregnancy tests,  allergy indicators,  Strep A Testing,  ovulation and fertility
testing,  tumor markers, drugs of abuse diagnostic kits, and infectious diseases
tests.

     Mr. George  received the degree of Master of Business  Administration  from
the Siddharth Institute of Industry and Administration of Bombay, India in 1979.
Mr.  George,  an  accountant  by  training,   has  comprehensive   knowledge  of
import-export markets and of financial operations, which has enabled him to work
in  fast-paced,  highly  diversified  environments. While working as the Finance
Manager  for  Sayco  &  Al Ordoba in 1981, Mr. George orchestrated international
transactions  involving  millions  of  dollars  with  such  multi-national
conglomerates  as  IBM, Xerox, Amoco Oil and Minnesota Mining and Manufacturing.
Mr.  George  was  Finance  and  Administration  Manager  for Al Orooba Technical
Trading  Co.  of  the  United  Arab  Emirates in 1982, Chief Accountant for Step
International  Marketing  Co.  of  Bombay, India in 1979, and Accountant for St.
George  Automobiles  and  Thankappan  and  Madhu, both of Kerala, India in 1977.

     DIRECTORSHIPS.

     At present, the Company has no directors or understanding with any
persons acting as directors who are in any way associated with Inamco.

ITEM 11. EXECUTIVE COMPENSATION.

        Summary of Cash and Certain Other Compensation

         The  following  table sets forth  certain  information  concerning  the
compensation  paid by the  Company for  services  rendered to the Company in all
capacities for the fiscal years ended December 31, 2002,  2001, 2000 and 1999 by
the Company's Chief Executive Officer:


                           SUMMARY COMPENSATION TABLE

<TABLE>
<CAPTION>

                                                                      LONG TERM
                                                                    COMPENSATION
                                          ANNUAL COMPENSATION           AWARDS
                                        -------------------------   -------------
                                                                     CLASS   "A"
                                                      ALL OTHER      COMMON STOCK
                                                       ANNUAL        RECEIVED  BY       VALUE OF
NAME AND PRINCIPAL POSITION      YEAR     SALARY    COMPENSATION       PRINCIPAL      COMPENSATION
----------------------------    ------- ---------- --------------   ---------------   --------------
<S>                              <C>   <C>         <C>              <C>               <C>
Varges George                    2002  $    --     $     --                -- .       $     10,000
President and Secretary          2001       --           --                --               50,000
                                 2000       --           --                --            1,100,000
                                 1999       --           --           1,000,000 sh.      2,350,000
</TABLE>


In accordance with the rules of the SEC, the compensation described in the above
table,  and that was paid to Mr. George,  was done so entirely in stock and does
not include any medical payments, group life insurance or any other benefit that
could be received by the sole  Executive  Officer of the  Company.  Furthermore,
there  has been no  compensation  awarded  to,  earned  by, or paid to any other
person,  acting as an employee,  since the Company's acquisition of Omni Assets,
Inc., on October 26, 1999.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

        SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS.

     As of May 9th, 2002,  the Company had a total number of shares  outstanding
equal to Twenty Seven Million Six Hundred Thousand  (27,600,000).  The following
table provides information pertaining to owners of more than five percent of any
class of the Company's voting stock.

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------
             (1)                      (2)                      (3)                     (4)
                               Name and Address          Amount and Nature         Percentage of
        Title of Class        of Beneficial Owner       of Beneficial Owner          Ownership
-------------------------------------------------------------------------------------------------------------
<S>                      <C>                              <C>                        <C>
     Common A            Inamco Services Corp.*            12,947,487                 46.91%
                                801 Montrose Ave.
                         South Plainfield, NJ 07080

     Common A            Advanced Diagnostics Inc.*         8,326,403                 30.17%
                               801 Montrose Ave.
                         South Plainfield, NJ 07080
</TABLE>

* It should be noted that Mr. Varges George is the sole shareholder and owner of
Inamco  Services  Corp.,  and  Advanced  Diagnostics  Inc.,  as described above.
Accordingly, Mr. George has direct control and ownership of 21,273,890 shares of
common stock, which represents approximately 77.07% of the Company's outstanding
common  shares (this does not take into consideration shares owned personally by
Mr.  George,  as  explained  below).


         Security ownership of management.

         As of  May  9th,  2002,  the  Company  had a  total  number  of  shares
outstanding equal to Twenty Seven Million Six Hundred Thousand (27,600,000). The
following table provides information  pertaining to shares beneficially owned by
all directors and nominees.


<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------
             (1)                      (2)                      (3)                     (4)
                               Name and Position          Amount and Nature         Percentage of
        Title of Class        of Beneficial Owner       of Beneficial Owner          Ownership
-------------------------------------------------------------------------------------------------------------
<S>                      <C>                              <C>                        <C>
         Common A              Varges George*                1,000,000                  3.62%
                               President/Secretary
</TABLE>

* Taking into  consideration  that Mr. Varges George is the sole  shareholder of
Inamco Services Corp., and Advanced  Diagnostics  Inc., it should be noted, that
with the  addition  of Mr.  George's  personal  shares  received  as  employment
compensation,  and  described  in other  sections of this Form 10, he has direct
control  of a total of  22,273,890  shares of  common  stock,  which  represents
approximately 80.70% of the Company's outstanding common shares.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

        TRANSACTIONS WITH MANAGEMENT AND OTHERS.

     The Company has not been  involved with or privy to any  transactions  with
any persons and/or  business  entities  since the Company's  acquisition of Omni
Assets,  Inc., on October 26, 1999. The  acquisition of Omni (Omni being defined
as a  "non-operating  public  shell"),  in  essence,  was by a  privately  owned
operating company,  and for reasons of filing this Form 10, that transaction was
deemed as a capital purchase by a privately-held  business. Since that purchase,
Inamco has been dormant with the exception of the limited  amount of activity as
described in Item. 1 "BUSINESS" - "General development of business" above.

     CERTAIN BUSINESS RELATIONSHIPS.

     The Company's sole executive, Mr. Varges George, is currently the president
and sole  shareholder of Inamco Services Corp. This management  company owns and
operates two separate and distinct  companies:  Medicos  Laboratories,  Inc. and
Advanced Diagnostics,  Inc., descriptions of both company's stated herein, under
Item 6. "DIRECTORS AND EXECUTIVE OFFICERS" - "Business Experience" of Mr. Varges
George.

     Although  the  Company's  sole  executive  officer and director is also the
owner of record, of Inamco Services Corp.,  Medicos  Laboratories,  and Advanced
Diagnostics,  neither he nor any other entity has made payment,  nor contributed
to the  Company's  gross  revenues  or  assets in any way  whatsoever  since the
acquisition  of Omni Assets,  Inc. on October 26, 1999. As explained in previous
sections of this Form 10 report,  net cash provided by loans from Mr. George was
approximately  $9,226  during the year ended  December 31, 2002,  and a total of
$8,068 is owing to Mr. George,  from the Company,  that is incurring 7% interest
on an annual basis while the debt is  outstanding.  Net cash proceeds from loans
by Mr. George were $525 during the year ended December 31, 2001.

     The Company's sole executive, Mr. George, is not a member of, or of counsel
to, a law firm, nor is he a partner to an investment  banking firm, where such a
company would need a retainer in order to perform certain services to Inamco.

     INDEBTEDNESS OF MANAGEMENT.

     The sole executive of Inamco,  Mr. Varges George,  has not been indebted to
the Company in any way whatsoever.

     TRANSACTIONS WITH PROMOTERS.

     The  Company  has had no need to employ  and/or  invoke the  services  of a
promoter.

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.

(a) 1. Financial Statements.

        Reference is made to the Index to Financial Statements under Item 8,
hereof.

     2. Financial Statement Schedules.

        The Financial Statement Schedules have been omitted either because they
are not required or because the information has been included in the notes to
the Financial Statements included in this Report on Form 10k.


3.
         EXHIBITS:

EXHIBIT NO.                                            DESCRIPTION
--------------                                         -----------
(a)               None.

(b) Reports on Form 8-K

None.

(c) Exhibits

See Item 14(a)(3) above.

(d) Financial Statement Schedules

See Item 14(a)(2) above.


                                   SIGNATURES

        Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on April 8, 2003.
Inamco International Corp.
A Delaware Corporation

By:    /s/  VARGES GEORGE
   --------------------------------
       Varges George
       Chief Executive Officer

         Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities indicated on April 8, 2003.

SIGNATURES                                TITLE
----------                                -----


By:    /s/  VARGES GEORGE                 President, Chief Executive
   ----------------------------           Officer and Director
       Varges George



<PAGE>